{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:18:43Z","timestamp":1777954723715,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.arteri.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:12:41Z","timestamp":1479255161000},"page":"22-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enfermedad renal cr\u00f3nica y dislipidemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Vicente","family":"Pascual","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adalberto","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ascaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mill\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2016.07.004_bib0495","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-154-5-201103010-00005","article-title":"Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk","volume":"154","author":"Clase","year":"2011","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0500","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000441737","article-title":"A review of pediatric chronic kidney disease","volume":"41","author":"Kaspar","year":"2016","journal-title":"Blood Purif."},{"key":"10.1016\/j.arteri.2016.07.004_bib0505","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.arteri.2016.07.004_bib0510","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: Results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrologia."},{"key":"10.1016\/j.arteri.2016.07.004_bib0515","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2016.07.004_bib0520","first-page":"WMC004769","article-title":"Accelerated atherosclerosis in patients with chronic kidney disease \u2014 the role of traditional and non-traditional risk factors","volume":"5","author":"Alam","year":"2014","journal-title":"WebmedCentral MEDICINE"},{"key":"10.1016\/j.arteri.2016.07.004_bib0525","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ahj.2008.02.024","article-title":"Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality","volume":"156","author":"McCullough","year":"2008","journal-title":"Am Heart J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0530","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.HYP.0000167121.14254.a0","article-title":"Kidney in early atherosclerosis","volume":"45","author":"Chade","year":"2005","journal-title":"Hypertension."},{"key":"10.1016\/j.arteri.2016.07.004_bib0535","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0540","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1681\/ASN.2012010037","article-title":"CKD and sudden cardiac death: Epidemiology, mechanisms, and therapeutic approaches","volume":"23","author":"Whitman","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0545","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: A systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0550","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0555","doi-asserted-by":"crossref","first-page":"e004251","DOI":"10.1136\/bmjopen-2013-004251","article-title":"Mortality in chronic kidney disease and renal replacement therapy: A population-based cohort study","volume":"4","author":"Neovius","year":"2014","journal-title":"BMJ Open."},{"key":"10.1016\/j.arteri.2016.07.004_bib0560","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.amjcard.2008.07.060","article-title":"The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years","volume":"102","author":"Rashidi","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0565","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2016.07.004_bib0570","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2016.07.004_bib0575","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/STROKEAHA.115.009861","article-title":"Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease. Chronic renal insufficiency cohort study","volume":"46","author":"Sandsmark","year":"2015","journal-title":"Stroke."},{"key":"10.1016\/j.arteri.2016.07.004_bib0580","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2016.07.004_bib0585","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/qjmed\/hcr026","article-title":"Stratifying risk in chronic kidney disease: An observational study of UK guidelines for measuring total proteinuria and albuminuria","volume":"104","author":"Methven","year":"2011","journal-title":"QJM."},{"key":"10.1016\/j.arteri.2016.07.004_bib0590","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0595","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jacc.2006.05.047","article-title":"Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction","volume":"48","author":"Wattanakit","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0600","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.113.007106","article-title":"Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease","volume":"130","author":"Sud","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2016.07.004_bib0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2012.05.007","volume":"223","author":"Perk","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0610","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association councils on Kidney in Cardiovascular disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2016.07.004_bib0615","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.ajkd.2014.04.024","article-title":"Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002","volume":"64","author":"Odden","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0620","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.numecd.2015.08.004","article-title":"A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients","volume":"25","author":"Testa","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0625","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4103\/1319-2442.128520","article-title":"Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia","volume":"25","author":"Sezer","year":"2014","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"10.1016\/j.arteri.2016.07.004_bib0630","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic Hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0635","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2010.03887.x","article-title":"Impact of allopurinol use on urate concentration and cardiovascular outcome","volume":"71","author":"Wei","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0640","doi-asserted-by":"crossref","first-page":"e55643","DOI":"10.1371\/journal.pone.0055643","article-title":"Association of dyslipidemia with renal outcomes in chronic kidney disease","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2016.07.004_bib0645","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","article-title":"Dyslipidemia and the progression of renal disease in chronic renal failure patients","volume":"99","author":"Cases","year":"2005","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.arteri.2016.07.004_bib0650","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MOL.0000000000000176","article-title":"LDL-cholesterol lowering and renal outcomes","volume":"26","author":"Waters","year":"2015","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0655","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0660","doi-asserted-by":"crossref","first-page":"346","DOI":"10.5551\/jat.20594","article-title":"Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus","volume":"21","author":"Sonoda","year":"2014","journal-title":"J Atheroscler Thromb."},{"key":"10.1016\/j.arteri.2016.07.004_bib0665","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1194\/jlr.P900003-JLR200","article-title":"Chronic kidney disease delays VLDL-apoB-100 particle catabolism: Potential role of apolipoprotein C-III","volume":"50","author":"Chan","year":"2009","journal-title":"J Lipid Res."},{"key":"10.1016\/j.arteri.2016.07.004_bib0670","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09674845.2012.12069133","article-title":"Serum small-dense LDL abnormalities in chronic renal disease patients","volume":"69","author":"Chu","year":"2012","journal-title":"Br J Biomed Sci."},{"key":"10.1016\/j.arteri.2016.07.004_bib0675","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874192401105010041","article-title":"Dyslipidemia associated with chronic kidney disease","volume":"5","author":"Tsimihodimos","year":"2011","journal-title":"Open Cardiovasc Med J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0680","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/ki.2010.311","article-title":"Dyslipidemia in children with chronic kidney disease: A report of the chronic kidney disease in children (CKiD) study","volume":"78","author":"Salaand","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0685","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2014.04.034","article-title":"Protein carbamylation in kidney disease: Pathogenesis and clinical implications","volume":"64","author":"Kalim","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0690","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","article-title":"Lipoprotein metabolism and lipid management in chronic kidney disease","volume":"18","author":"Kwan","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0695","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-3-319-09665-0_13","article-title":"High-density lipoprotein: Structural and functional changes under uremic conditions and the therapeutic consequences","volume":"224","author":"Schuchardt","year":"2015","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0700","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.1992.204","article-title":"Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure","volume":"41","author":"Sent\u00ed","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0705","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia alters HDL composition and function","volume":"22","author":"Holzer","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0710","doi-asserted-by":"crossref","first-page":"457","DOI":"10.7326\/0003-4819-129-6-199809150-00006","article-title":"Increased serum lipoprotein(a) levels in patients with early renal failure","volume":"129","author":"Sechi","year":"1998","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0715","unstructured":"Merkens LS, Myrie SB, Steiner RD, Mymin D. Sitosterolemia 2013. Apr 4. En: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean, LHE et al., editores. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016 [consultado 20 Abr 2016]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK131810\/"},{"key":"10.1016\/j.arteri.2016.07.004_bib0720","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2215\/CJN.05170511","article-title":"Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients","volume":"7","author":"Rogacev","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0725","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jacc.2015.03.551","article-title":"Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients","volume":"65","author":"Silbernagel","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.jrn.2013.11.001","article-title":"Toward individualized cholesterol-lowering treatment in end-stage renal disease","volume":"24","author":"Silbernagel","year":"2014","journal-title":"J Ren Nutr."},{"key":"10.1016\/j.arteri.2016.07.004_bib0735","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V981482","article-title":"Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency","volume":"9","author":"Samuelsson","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0740","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2016.07.004_bib0745","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy \u2014 a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.arteri.2016.07.004_bib0750","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1253\/circj.CJ-14-0789","article-title":"Differential effects of strong and regular statins on the clinical outcome of patients with chronic kidney disease following coronary stent implantation \u2014 the Kumamoto Intervention Conference Study (KICS) Registry","volume":"79","author":"Ishii","year":"2015","journal-title":"Circ J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0755","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2261-14-19","article-title":"Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: A systematic review and meta-analysis of randomized clinical trials","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cardiovasc Disord."},{"key":"10.1016\/j.arteri.2016.07.004_bib0760","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.amjcard.2012.07.021","article-title":"Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI\/CABG Registry Cohort-2)","volume":"110","author":"Natsuaki","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0765","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2016.07.004_bib0770","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT Study","volume":"4","author":"Jardine","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.arteri.2016.07.004_bib0775","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ndt\/gfh735","article-title":"Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.arteri.2016.07.004_bib0780","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0785","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0790","first-page":"CD004289","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","volume":"9","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arteri.2016.07.004_bib0795","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2016.07.004_bib0800","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-139X.2008.00455.x","article-title":"Sudden cardiac death and dialysis patients","volume":"21","author":"Herzog","year":"2008","journal-title":"Semin Dial."},{"key":"10.1016\/j.arteri.2016.07.004_bib0805","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nm0110-38","article-title":"Kidney complications: Why don\u2019t statins always work?","volume":"16","author":"Karumanchi","year":"2010","journal-title":"Nat Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0810","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.arteri.2016.07.004_bib0815","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.arteri.2016.07.004_bib0820","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0825","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.amjcard.2014.05.033","article-title":"Meta-analysis of the effect of statins on renal function","volume":"114","author":"Geng","year":"2014","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0830","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0835","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0840","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5551\/jat.3764","article-title":"Effects of pitavastatin (LIVALO Tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study","volume":"17","author":"Kimura","year":"2010","journal-title":"J Atheroscler Thromb."},{"key":"10.1016\/j.arteri.2016.07.004_bib0845","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1463-1326.2011.01477.x","article-title":"Comparative long-term efficacy and tolerability of pitavastatin 4mg and atorvastatin 20-40mg in patients with type 2 diabetes mellitus and combined dyslipidemia","volume":"13","author":"Gumprecht","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.arteri.2016.07.004_bib0850","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial","volume":"3","author":"De Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0855","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.12296","article-title":"Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy","volume":"6","author":"Takazakura","year":"2015","journal-title":"J Diabetes Investig."},{"key":"10.1016\/j.arteri.2016.07.004_bib0860","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1463-1326.2012.01566.x","article-title":"Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy","volume":"14","author":"Kimura","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.arteri.2016.07.004_bib0865","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-015-0328-z","article-title":"Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: A post hoc analysis of the SAGE trial","volume":"32","author":"Deedwania","year":"2015","journal-title":"Drugs Aging."},{"key":"10.1016\/j.arteri.2016.07.004_bib0870","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacc.2013.09.017","article-title":"Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease","volume":"63","author":"Han","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0875","doi-asserted-by":"crossref","first-page":"e111397","DOI":"10.1371\/journal.pone.0111397","article-title":"Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: Updated study-level meta-analysis of 13 randomized controlled trials","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2016.07.004_bib0880","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner \u017d","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0885","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.00780306","article-title":"Management of dyslipidemias in patients with diabetes and chronic kidney disease","volume":"1","author":"Molitch","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0890","unstructured":"Tannock L. Dyslipidemia in chronic kidney disease. En: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JL, Koch, C, et al., editores. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2015 [consultado 30 Mar 2016]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305899\/"},{"key":"10.1016\/j.arteri.2016.07.004_bib0895","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: A systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0900","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0905","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jacc.2008.03.025","article-title":"Managing dyslipidemia in chronic kidney disease","volume":"51","author":"Harper","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0910","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia."},{"key":"10.1016\/j.arteri.2016.07.004_bib0915","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care."},{"key":"10.1016\/j.arteri.2016.07.004_bib0920","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0925","first-page":"1250","article-title":"Niacin and progression of CKD","volume":"87","author":"Streja","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0930","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2215\/CJN.07341009","article-title":"Hypophosphatemic effect of niacin in patients without renal failure: A randomized trial","volume":"5","author":"Maccubbin","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0935","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0940","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin\/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2016.07.004_bib0945","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ki.2014.383","article-title":"Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: A post hoc analysis of the AIM-HIGH trial","volume":"87","author":"Kalil","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2016.07.004_bib0950","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2016.07.004_bib0955","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/clp.11.50","article-title":"n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease","volume":"6","author":"Christensen","year":"2011","journal-title":"Clin Lipidol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0960","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2215\/CJN.00630206","article-title":"N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: A randomized, placebo-controlled intervention trial","volume":"1","author":"Svensson","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0965","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00228-015-1976-y","article-title":"Effect of fish oil supplement in maintenance hemodialysis patients: A systematic review and meta-analysis of published randomized controlled trials","volume":"72","author":"He","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.arteri.2016.07.004_bib0970","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2016.07.004_bib0975","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/eci.12230","article-title":"Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease","volume":"44","author":"Almquist","year":"2014","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.arteri.2016.07.004_bib0980","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/eurheartj\/ehv393","article-title":"Lowering cholesterol in chronic kidney disease: Is it safe and effective?","volume":"36","author":"Wong","year":"2015","journal-title":"Eur Heart J."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916816301012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916816301012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T19:03:51Z","timestamp":1657739031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916816301012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0214916816301012"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2016.07.004","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad renal cr\u00f3nica y dislipidemia","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}